Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)

Novartis

Status: Completed

Conditions: Neonatal Onset Multisystem Inflam Disease (NOMID); Familial Cold Autoinflam Syn (FCAS); Cryopyrin-associated Periodic Syndromes (CAPS); Muckle-wells Syn (MWS)

Study type: Observational

Funder types: Industry

Identifiers

NCT01213641

CACZ885D2401

Details and patient eligibility

About

The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.

Enrollment: 288 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients receiving Ilaris (canakinumab) at the time of enrollment as part of medical care

Exclusion criteria

• Local regulations in some locations may exclude patients who receive Ilaris for a non-approved indication
• Other protocol-defined inclusion/exclusion criteria may apply